Shopping Cart 0
Cart Subtotal
USD 0

Gilead Sciences Inc (GILD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in different stages of development. Gilead strives to develop products that offer improved methods of delivery, enhanced resistance profile, minimized side effects and greater efficiency. Gilead sells its products through marketing subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc (GILD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 25

Asset Purchase 25

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 25

Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 26

Venture Financing 28

Precision BioSciences Raises USD110 Million in Venture Financing 28

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 31

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 33

Hookipa Biotech Raises USD58.8 Million in Series C Financing 35

Cell Design Labs Raises USD34.4 Million in Venture Financing 37

Cell Design Labs Raises USD22.9 Million in Venture Financing 38

Kite Pharma Raises USD 20 Million In Series A Financing 39

Kite Pharma Raises USD 0.2 Million In Venture Financing 40

Partnerships 41

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 41

Janssen Amends Licensing Agreement with Gilead for STR 42

Gilead Sciences and Precision BioSciences Enter into Co-Development Agreement 43

Kite Pharma and Gadeta Enter into Co-Development Agreement 44

Gilead Sciences and Verily Life Enter into Partnership Agreement 45

Kite Pharma Enters into Partnership with Pfizer 46

Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 47

X-Chem Enters into Co-Development Agreement with Gilead Sciences 48

Grupo Biotoscana Expands Agreement with Gilead Sciences 49

Spring Bank Pharma Enters into Agreement with Gilead Sciences 50

Kite Pharma Forms Joint Venture with Fosun Pharma 51

Kite Pharma Enters into Agreement with Vitruvian Networks 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Kite Pharma Enters into Agreement with Genentech 54

Gilead Sciences Enters into Co-Development Agreement with Galapagos 55

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 56

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 57

Kite Pharma Enters into Research Agreement with GE Global Research 58

Spring Bank Pharma Enters into Agreement with Gilead Sciences 59

X-Rx Enters into Agreement with Gilead Sciences 60

Gilead Sciences Partners with WuXi PharmaTech 61

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 62

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 63

Adimab Enters into Research Agreement with Kite Pharma 64

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 65

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 66

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 67

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 68

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 70

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 71

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 72

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 73

Adimab Enters Into Co-Development Agreement With Gilead Sciences 74

Licensing Agreements 75

Kite Pharma Enters into Licensing Agreement with HiFiBiO Therapeutics 75

Gilead Sciences Enters into Licensing Agreement with Trianni 76

Gilead Sciences Enters into Licensing Agreement with Hookipa Biotech 77

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 78

Cypralis Enters into Licensing Agreement with Gilead Sciences 80

Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 81

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 82

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 83

Genmab Enters into Licensing Agreement with Gilead Sciences 84

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 85

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 86

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 87

Kite Pharma Exercises Option for Licensing Agreement with Adimab 88

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 89

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 92

Amgen Enters into Licensing Agreement with Kite Pharma 93

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 95

Janssen Expands Licensing Agreement with Gilead 96

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 97

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 98

Gilead Sciences Expands Licensing Agreement with Mylan Labs 99

Gilead Sciences Expands Licensing Agreement with Strides Shasun 100

Gilead Sciences Enters into Licensing Agreement with Cipla 102

Gilead Sciences Expands Licensing Agreement For Hepatitis C Drug, Sovaldi 103

Gilead Sciences Expands Licensing Agreement with Sun Pharma 104

Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 105

Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 106

Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 107

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 108

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 109

Gilead Sciences Enters Into Licensing Agreement With Polyphor 110

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 111

Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 112

Gilead Sciences Expands Licensing Agreement with Mylan Labs 113

Biocon Enters into Licensing Agreement with Gilead Sciences 114

Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 115

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 116

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 117

Gilead Sciences Enters into Licensing Agreement with Hetero Labs 118

Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 119

Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 120

Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 121

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 122

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 124

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 125

Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 126

Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 127

Equity Offering 129

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 129

Galapagos Raises USD425 Million in Private Placement of Shares 131

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 132

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 134

Kite Pharma Raises USD146.62 Million in IPO 136

Debt Offering 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 140

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 142

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 144

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 146

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 148

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 150

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 152

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 154

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 156

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 158

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 160

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 162

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 164

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 166

Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 168

Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 170

Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 172

Gilead Sciences Completes Public Offering Of Notes Due 2019 For USD 500 Million 174

Gilead Sciences Completes Public Offering Of Notes Due 2044 For USD 1.75 Billion 176

Gilead Sciences Completes Public Offering Of Notes Due 2024 For USD 1.75 Billion 178

Asset Transactions 180

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 180

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 182

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 183

Acquisition 185

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 185

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 187

Gilead Sciences May Acquire Incyte 189

Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 190

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 191

Kite Pharma Acquires T-Cell Factory 192

Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 193

Gilead Sciences Completes Acquisition Of Pharmasset For USD 11.2 Billion 195

Gilead Sciences Inc - Key Competitors 197

Gilead Sciences Inc - Key Employees 198

Gilead Sciences Inc - Locations And Subsidiaries 200

Head Office 200

Other Locations & Subsidiaries 200

Joint Venture 204

Recent Developments 205

Strategy And Business Planning 205

Oct 04, 2018: Kite partners with HiFiBiO Therapeutics on TCR-based cancer therapies 205

Financial Announcements 206

Jul 25, 2018: Gilead Sciences Announces Second Quarter 2018 Financial Results 206

May 01, 2018: Gilead Sciences Announces First Quarter 2018 Financial Results 209

Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results 211

Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 214

Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 216

May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 218

Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 220

Corporate Communications 222

Aug 14, 2018: Gilead Sciences Announces Executive Promotions 222

Jul 25, 2018: Gilead Sciences announces CEO John F. Milligan to step down 223

Jun 11, 2018: Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia 224

Jun 04, 2018: Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy 225

May 09, 2018: Harish Manwani Joins Gilead Sciences Board of Directors 226

Mar 12, 2018: Gilead Sciences Announces Senior Management Changes 227

Feb 22, 2018: Gilead Sciences Announces Senior Management Change 229

Feb 01, 2018: Gilead Sciences Appoints Jacqueline K. Barton As Board of Directors 230

Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors 231

Dec 04, 2017: Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States 232

Sep 27, 2017: Kevin Young CBE, Gileads Chief Operating Officer, to Retire 233

Legal and Regulatory 234

Apr 25, 2018: Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck's "Unclean Hands" 234

Apr 19, 2018: KEI sues NIH over license of CD30 CAR T patents to Gilead 235

Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL 236

Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck 237

Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer 238

Government and Public Interest 239

Mar 05, 2018: Epilepsy Foundation Awards $200,000 at Shark Tank Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care 239

Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research 240

Oct 16, 2017: Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research 241

Jan 10, 2017: Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research 242

Jan 09, 2017: Mercy Philadelphia Hospital Receives FOCUS Award from Gilead Sciences 244

Product News 245

10/25/2017: Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy 245

10/19/2017: BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy 247

10/18/2017: City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell Therapy for Adult Patients with Certain Types of Large B-cell Lymphoma 248

10/18/2017: Kites Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy 249

10/18/2017: UChicago Medicine first site in Illinois offering pioneering CAR T-cell therapy for cancer 251

06/19/2017: Gilead Receives Approval in Canada for VEMLIDY (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection 253

06/14/2017: Court Decides It Lacks Jurisdiction Before FDA Approval Occurs 254

05/26/2017: Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel 255

05/17/2017: Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting 256

04/21/2017: Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 258

04/02/2017: Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting 259

03/30/2017: Kite to Present on Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting 261

03/06/2018: Broad spectrum antiviral drug inhibits a range of emerging coronaviruses 262

03/06/2017: John Theurer Cancer Center part of multi-center study with National Cancer Institute and Kite Pharma for CAR-T Cell Therapy Study Showing Very Impressive Results in Aggressive Lymphoma Refractory to Chemotherapy 263

02/28/2017: Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma 264

02/07/2018: ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir 266

01/11/2017: European Commission Grants Marketing Authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection 267

01/05/2017: Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors 268

Product Approvals 269

Jul 31, 2017: Kite Files the Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel 269

Apr 10, 2017: Gileads Vemlidy Rejects For Use Within NHS Scotland 270

Mar 31, 2017: Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL) 271

Clinical Trials 272

Mar 04, 2018: Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys 272

Oct 24, 2017: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis 273

Oct 20, 2017: Gilead Announces Presentations on Vemlidy at The Liver Meeting 2017 274

Aug 07, 2017: Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union 275

Aug 02, 2017: Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5) 276

Jun 24, 2017: European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL) 277

Jun 05, 2017: HalioDx highlights use of Immunosign to define CAR T-cell therapy signature in tumor at ASCO 2017 278

Jun 05, 2017: Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 279

Apr 20, 2017: Gilead Presents Data at the International Liver Congress 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread 280

Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017 281

Apr 06, 2017: Kite Wins 'Clinical Trial Result of the Year' for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards 282

Feb 13, 2017: Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors 283

Jan 05, 2017: Immune cell therapy shows promising results for lymphoma patients 284

Other Significant Developments 285

Feb 28, 2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan 285

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 286

Oct 17, 2017: As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada 287

Appendix 289

Methodology 289

About GlobalData 289

Contact Us 289

Disclaimer 289


List Of Figure

List of Figures

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 25

Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 26

Precision BioSciences Raises USD110 Million in Venture Financing 28

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 31

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 33

Hookipa Biotech Raises USD58.8 Million in Series C Financing 35

Cell Design Labs Raises USD34.4 Million in Venture Financing 37

Cell Design Labs Raises USD22.9 Million in Venture Financing 38

Kite Pharma Raises USD 20 Million In Series A Financing 39

Kite Pharma Raises USD 0.2 Million In Venture Financing 40

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 41

Janssen Amends Licensing Agreement with Gilead for STR 42

Gilead Sciences and Precision BioSciences Enter into Co-Development Agreement 43

Kite Pharma and Gadeta Enter into Co-Development Agreement 44

Gilead Sciences and Verily Life Enter into Partnership Agreement 45

Kite Pharma Enters into Partnership with Pfizer 46

Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 47

X-Chem Enters into Co-Development Agreement with Gilead Sciences 48

Grupo Biotoscana Expands Agreement with Gilead Sciences 49

Spring Bank Pharma Enters into Agreement with Gilead Sciences 50

Kite Pharma Forms Joint Venture with Fosun Pharma 51

Kite Pharma Enters into Agreement with Vitruvian Networks 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Kite Pharma Enters into Agreement with Genentech 54

Gilead Sciences Enters into Co-Development Agreement with Galapagos 55

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 56

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 57

Kite Pharma Enters into Research Agreement with GE Global Research 58

Spring Bank Pharma Enters into Agreement with Gilead Sciences 59

X-Rx Enters into Agreement with Gilead Sciences 60

Gilead Sciences Partners with WuXi PharmaTech 61

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 62

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 63

Adimab Enters into Research Agreement with Kite Pharma 64

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 65

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 66

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 67

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 68

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 70

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 71

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 72

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 73

Adimab Enters Into Co-Development Agreement With Gilead Sciences 74

Kite Pharma Enters into Licensing Agreement with HiFiBiO Therapeutics 75

Gilead Sciences Enters into Licensing Agreement with Trianni 76

Gilead Sciences Enters into Licensing Agreement with Hookipa Biotech 77

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 78

Cypralis Enters into Licensing Agreement with Gilead Sciences 80

Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 81

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 82

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 83

Genmab Enters into Licensing Agreement with Gilead Sciences 84

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 85

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 86

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 87

Kite Pharma Exercises Option for Licensing Agreement with Adimab 88

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 89

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 92

Amgen Enters into Licensing Agreement with Kite Pharma 93

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 95

Janssen Expands Licensing Agreement with Gilead 96

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 97

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 98

Gilead Sciences Expands Licensing Agreement with Mylan Labs 99

Gilead Sciences Expands Licensing Agreement with Strides Shasun 100

Gilead Sciences Enters into Licensing Agreement with Cipla 102

Gilead Sciences Expands Licensing Agreement For Hepatitis C Drug, Sovaldi 103

Gilead Sciences Expands Licensing Agreement with Sun Pharma 104

Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 105

Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 106

Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 107

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 108

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 109

Gilead Sciences Enters Into Licensing Agreement With Polyphor 110

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 111

Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 112

Gilead Sciences Expands Licensing Agreement with Mylan Labs 113

Biocon Enters into Licensing Agreement with Gilead Sciences 114

Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 115

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 116

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 117

Gilead Sciences Enters into Licensing Agreement with Hetero Labs 118

Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 119

Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 120

Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 121

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 122

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 124

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 125

Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 126

Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 127

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 129

Galapagos Raises USD425 Million in Private Placement of Shares 131

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 132

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 134

Kite Pharma Raises USD146.62 Million in IPO 136

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 140

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 142

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 144

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 146

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 148

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 150

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 152

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 154

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 156

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 158

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 160

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 162

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 164

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 166

Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 168

Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 170

Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 172

Gilead Sciences Completes Public Offering Of Notes Due 2019 For USD 500 Million 174

Gilead Sciences Completes Public Offering Of Notes Due 2044 For USD 1.75 Billion 176

Gilead Sciences Completes Public Offering Of Notes Due 2024 For USD 1.75 Billion 178

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 180

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 182

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 183

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 185

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 187

Gilead Sciences May Acquire Incyte 189

Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 190

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 191

Kite Pharma Acquires T-Cell Factory 192

Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 193

Gilead Sciences Completes Acquisition Of Pharmasset For USD 11.2 Billion 195

Gilead Sciences Inc, Key Competitors 197

Gilead Sciences Inc, Key Employees 198

Gilead Sciences Inc, Other Locations 200

Gilead Sciences Inc, Subsidiaries 200

Gilead Sciences Inc, Joint Venture 204

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Gilead Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in different stages of development. Gilead strives to develop products that offer improved methods of delivery, enhanced resistance profile, minimized side effects and greater efficiency. Gilead sells its products through marketing subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc (GILD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 25

Asset Purchase 25

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 25

Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 26

Venture Financing 28

Precision BioSciences Raises USD110 Million in Venture Financing 28

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 31

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 33

Hookipa Biotech Raises USD58.8 Million in Series C Financing 35

Cell Design Labs Raises USD34.4 Million in Venture Financing 37

Cell Design Labs Raises USD22.9 Million in Venture Financing 38

Kite Pharma Raises USD 20 Million In Series A Financing 39

Kite Pharma Raises USD 0.2 Million In Venture Financing 40

Partnerships 41

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 41

Janssen Amends Licensing Agreement with Gilead for STR 42

Gilead Sciences and Precision BioSciences Enter into Co-Development Agreement 43

Kite Pharma and Gadeta Enter into Co-Development Agreement 44

Gilead Sciences and Verily Life Enter into Partnership Agreement 45

Kite Pharma Enters into Partnership with Pfizer 46

Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 47

X-Chem Enters into Co-Development Agreement with Gilead Sciences 48

Grupo Biotoscana Expands Agreement with Gilead Sciences 49

Spring Bank Pharma Enters into Agreement with Gilead Sciences 50

Kite Pharma Forms Joint Venture with Fosun Pharma 51

Kite Pharma Enters into Agreement with Vitruvian Networks 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Kite Pharma Enters into Agreement with Genentech 54

Gilead Sciences Enters into Co-Development Agreement with Galapagos 55

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 56

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 57

Kite Pharma Enters into Research Agreement with GE Global Research 58

Spring Bank Pharma Enters into Agreement with Gilead Sciences 59

X-Rx Enters into Agreement with Gilead Sciences 60

Gilead Sciences Partners with WuXi PharmaTech 61

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 62

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 63

Adimab Enters into Research Agreement with Kite Pharma 64

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 65

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 66

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 67

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 68

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 70

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 71

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 72

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 73

Adimab Enters Into Co-Development Agreement With Gilead Sciences 74

Licensing Agreements 75

Kite Pharma Enters into Licensing Agreement with HiFiBiO Therapeutics 75

Gilead Sciences Enters into Licensing Agreement with Trianni 76

Gilead Sciences Enters into Licensing Agreement with Hookipa Biotech 77

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 78

Cypralis Enters into Licensing Agreement with Gilead Sciences 80

Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 81

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 82

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 83

Genmab Enters into Licensing Agreement with Gilead Sciences 84

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 85

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 86

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 87

Kite Pharma Exercises Option for Licensing Agreement with Adimab 88

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 89

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 92

Amgen Enters into Licensing Agreement with Kite Pharma 93

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 95

Janssen Expands Licensing Agreement with Gilead 96

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 97

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 98

Gilead Sciences Expands Licensing Agreement with Mylan Labs 99

Gilead Sciences Expands Licensing Agreement with Strides Shasun 100

Gilead Sciences Enters into Licensing Agreement with Cipla 102

Gilead Sciences Expands Licensing Agreement For Hepatitis C Drug, Sovaldi 103

Gilead Sciences Expands Licensing Agreement with Sun Pharma 104

Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 105

Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 106

Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 107

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 108

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 109

Gilead Sciences Enters Into Licensing Agreement With Polyphor 110

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 111

Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 112

Gilead Sciences Expands Licensing Agreement with Mylan Labs 113

Biocon Enters into Licensing Agreement with Gilead Sciences 114

Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 115

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 116

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 117

Gilead Sciences Enters into Licensing Agreement with Hetero Labs 118

Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 119

Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 120

Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 121

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 122

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 124

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 125

Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 126

Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 127

Equity Offering 129

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 129

Galapagos Raises USD425 Million in Private Placement of Shares 131

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 132

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 134

Kite Pharma Raises USD146.62 Million in IPO 136

Debt Offering 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 140

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 142

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 144

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 146

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 148

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 150

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 152

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 154

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 156

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 158

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 160

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 162

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 164

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 166

Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 168

Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 170

Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 172

Gilead Sciences Completes Public Offering Of Notes Due 2019 For USD 500 Million 174

Gilead Sciences Completes Public Offering Of Notes Due 2044 For USD 1.75 Billion 176

Gilead Sciences Completes Public Offering Of Notes Due 2024 For USD 1.75 Billion 178

Asset Transactions 180

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 180

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 182

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 183

Acquisition 185

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 185

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 187

Gilead Sciences May Acquire Incyte 189

Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 190

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 191

Kite Pharma Acquires T-Cell Factory 192

Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 193

Gilead Sciences Completes Acquisition Of Pharmasset For USD 11.2 Billion 195

Gilead Sciences Inc - Key Competitors 197

Gilead Sciences Inc - Key Employees 198

Gilead Sciences Inc - Locations And Subsidiaries 200

Head Office 200

Other Locations & Subsidiaries 200

Joint Venture 204

Recent Developments 205

Strategy And Business Planning 205

Oct 04, 2018: Kite partners with HiFiBiO Therapeutics on TCR-based cancer therapies 205

Financial Announcements 206

Jul 25, 2018: Gilead Sciences Announces Second Quarter 2018 Financial Results 206

May 01, 2018: Gilead Sciences Announces First Quarter 2018 Financial Results 209

Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results 211

Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 214

Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 216

May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 218

Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 220

Corporate Communications 222

Aug 14, 2018: Gilead Sciences Announces Executive Promotions 222

Jul 25, 2018: Gilead Sciences announces CEO John F. Milligan to step down 223

Jun 11, 2018: Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia 224

Jun 04, 2018: Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy 225

May 09, 2018: Harish Manwani Joins Gilead Sciences Board of Directors 226

Mar 12, 2018: Gilead Sciences Announces Senior Management Changes 227

Feb 22, 2018: Gilead Sciences Announces Senior Management Change 229

Feb 01, 2018: Gilead Sciences Appoints Jacqueline K. Barton As Board of Directors 230

Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors 231

Dec 04, 2017: Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States 232

Sep 27, 2017: Kevin Young CBE, Gileads Chief Operating Officer, to Retire 233

Legal and Regulatory 234

Apr 25, 2018: Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck's "Unclean Hands" 234

Apr 19, 2018: KEI sues NIH over license of CD30 CAR T patents to Gilead 235

Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL 236

Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck 237

Sep 19, 2017: GHJP Closes Two-Year FOIA Case Against Drug Manufacturer 238

Government and Public Interest 239

Mar 05, 2018: Epilepsy Foundation Awards $200,000 at Shark Tank Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care 239

Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research 240

Oct 16, 2017: Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research 241

Jan 10, 2017: Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research 242

Jan 09, 2017: Mercy Philadelphia Hospital Receives FOCUS Award from Gilead Sciences 244

Product News 245

10/25/2017: Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy 245

10/19/2017: BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy 247

10/18/2017: City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell Therapy for Adult Patients with Certain Types of Large B-cell Lymphoma 248

10/18/2017: Kites Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy 249

10/18/2017: UChicago Medicine first site in Illinois offering pioneering CAR T-cell therapy for cancer 251

06/19/2017: Gilead Receives Approval in Canada for VEMLIDY (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection 253

06/14/2017: Court Decides It Lacks Jurisdiction Before FDA Approval Occurs 254

05/26/2017: Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel 255

05/17/2017: Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting 256

04/21/2017: Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 258

04/02/2017: Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting 259

03/30/2017: Kite to Present on Axicabtagene Ciloleucel at the 2017 American Association of Cancer Research Annual Meeting 261

03/06/2018: Broad spectrum antiviral drug inhibits a range of emerging coronaviruses 262

03/06/2017: John Theurer Cancer Center part of multi-center study with National Cancer Institute and Kite Pharma for CAR-T Cell Therapy Study Showing Very Impressive Results in Aggressive Lymphoma Refractory to Chemotherapy 263

02/28/2017: Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma 264

02/07/2018: ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir 266

01/11/2017: European Commission Grants Marketing Authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection 267

01/05/2017: Kite Pharma Enhances Commercial Expertise with the Appointment of Ian T. Clark to its Board of Directors 268

Product Approvals 269

Jul 31, 2017: Kite Files the Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel 269

Apr 10, 2017: Gileads Vemlidy Rejects For Use Within NHS Scotland 270

Mar 31, 2017: Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL) 271

Clinical Trials 272

Mar 04, 2018: Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys 272

Oct 24, 2017: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis 273

Oct 20, 2017: Gilead Announces Presentations on Vemlidy at The Liver Meeting 2017 274

Aug 07, 2017: Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union 275

Aug 02, 2017: Kite Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5) 276

Jun 24, 2017: European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL) 277

Jun 05, 2017: HalioDx highlights use of Immunosign to define CAR T-cell therapy signature in tumor at ASCO 2017 278

Jun 05, 2017: Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 279

Apr 20, 2017: Gilead Presents Data at the International Liver Congress 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread 280

Apr 20, 2017: Gilead to Present Additional Clinical Data on Selonsertib at The International Liver Congress 2017 281

Apr 06, 2017: Kite Wins 'Clinical Trial Result of the Year' for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards 282

Feb 13, 2017: Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors 283

Jan 05, 2017: Immune cell therapy shows promising results for lymphoma patients 284

Other Significant Developments 285

Feb 28, 2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan 285

Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs 286

Oct 17, 2017: As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada 287

Appendix 289

Methodology 289

About GlobalData 289

Contact Us 289

Disclaimer 289


List Of Figure

List of Figures

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Gilead Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Gilead Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 14

Gilead Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 16

Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Kite Pharma Acquires Agensys Research Facilities from Astellas Pharma 25

Gilead Sciences Acquires Farnesoid X Receptor Program from Phenex Pharma 26

Precision BioSciences Raises USD110 Million in Venture Financing 28

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 31

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 33

Hookipa Biotech Raises USD58.8 Million in Series C Financing 35

Cell Design Labs Raises USD34.4 Million in Venture Financing 37

Cell Design Labs Raises USD22.9 Million in Venture Financing 38

Kite Pharma Raises USD 20 Million In Series A Financing 39

Kite Pharma Raises USD 0.2 Million In Venture Financing 40

Kite Pharma Enters into Option Agreement with Netherlands Cancer Institute to License T Cell Receptor Cancer Immunotherapy Product Candidates 41

Janssen Amends Licensing Agreement with Gilead for STR 42

Gilead Sciences and Precision BioSciences Enter into Co-Development Agreement 43

Kite Pharma and Gadeta Enter into Co-Development Agreement 44

Gilead Sciences and Verily Life Enter into Partnership Agreement 45

Kite Pharma Enters into Partnership with Pfizer 46

Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 47

X-Chem Enters into Co-Development Agreement with Gilead Sciences 48

Grupo Biotoscana Expands Agreement with Gilead Sciences 49

Spring Bank Pharma Enters into Agreement with Gilead Sciences 50

Kite Pharma Forms Joint Venture with Fosun Pharma 51

Kite Pharma Enters into Agreement with Vitruvian Networks 52

Kite Pharma Enters into R&D Agreement with National Cancer Institute 53

Kite Pharma Enters into Agreement with Genentech 54

Gilead Sciences Enters into Co-Development Agreement with Galapagos 55

Kite Pharma Enters into Research Agreement with Leiden University Medical Center 56

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 57

Kite Pharma Enters into Research Agreement with GE Global Research 58

Spring Bank Pharma Enters into Agreement with Gilead Sciences 59

X-Rx Enters into Agreement with Gilead Sciences 60

Gilead Sciences Partners with WuXi PharmaTech 61

Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 62

Kite Pharma Enters into Co-Development Agreement with Bluebird bio 63

Adimab Enters into Research Agreement with Kite Pharma 64

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 65

Kite Pharma Extends Research Agreement with Tel Aviv Medical Center to Develop Novel Chimeric Antigen Receptor (CAR) 66

Kite Pharma Enters into Research Agreement with Tel Aviv Medical Center 67

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 68

Menarini Enters Into Commercialization Agreement With Gilead Sciences For Ranexa 70

Cancer Genetics Enters Into Agreement With Gilead Sciences To Provide Clinical Trial Services 71

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 72

AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 73

Adimab Enters Into Co-Development Agreement With Gilead Sciences 74

Kite Pharma Enters into Licensing Agreement with HiFiBiO Therapeutics 75

Gilead Sciences Enters into Licensing Agreement with Trianni 76

Gilead Sciences Enters into Licensing Agreement with Hookipa Biotech 77

Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 78

Cypralis Enters into Licensing Agreement with Gilead Sciences 80

Gilead Sciences Enters into Licensing Agreement with Medicines Patent Pool 81

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 82

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 83

Genmab Enters into Licensing Agreement with Gilead Sciences 84

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 85

Kite Pharma Enters into Licensing Agreement with Regents of the University of California 86

Kite Pharma Enters into Licensing Agreement with Cell Design Labs 87

Kite Pharma Exercises Option for Licensing Agreement with Adimab 88

Kite Pharma Extends Licensing Agreement with Alpine Immune Sciences 89

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 90

Natco Pharma Enters into Licensing Agreement with Gilead Sciences 92

Amgen Enters into Licensing Agreement with Kite Pharma 93

Kite Pharma Enters into Licensing Agreement with National Institutes of Health for T Cell Receptor-Based Products 95

Janssen Expands Licensing Agreement with Gilead 96

Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 97

Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 98

Gilead Sciences Expands Licensing Agreement with Mylan Labs 99

Gilead Sciences Expands Licensing Agreement with Strides Shasun 100

Gilead Sciences Enters into Licensing Agreement with Cipla 102

Gilead Sciences Expands Licensing Agreement For Hepatitis C Drug, Sovaldi 103

Gilead Sciences Expands Licensing Agreement with Sun Pharma 104

Gilead Sciences Expands Licensing Agreement with SeQuent Scientific 105

Theraclone Sciences Enters into Licensing Agreement with Gilead Sciences 106

Parion Sciences Enters Into Licensing Agreement With Gilead Sciences 107

Kite Pharma Enters into Licensing Agreement with Cabaret Biotech 108

Kite Pharma Enters into Licensing Agreement with National Institutes of Health 109

Gilead Sciences Enters Into Licensing Agreement With Polyphor 110

Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 111

Medicines Patent Pool Expands Licensing Agreement with Gilead Sciences 112

Gilead Sciences Expands Licensing Agreement with Mylan Labs 113

Biocon Enters into Licensing Agreement with Gilead Sciences 114

Gilead Sciences Enters into Licensing Agreement with Strides Arcolab 115

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 116

Gilead Sciences Enters into Licensing Agreement with Cadila Healthcare 117

Gilead Sciences Enters into Licensing Agreement with Hetero Labs 118

Gilead Sciences Enters Into Licensing Agreement With CURx Pharma 119

Shilpa Medicare Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences For HIV Drugs 120

Shasun Pharma Enters Into Licensing Agreement With Medicines Patent Pool And Gilead Sciences 121

MacroGenics Enters Into Licensing Agreement With Gilead Sciences For DART Technology 122

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 124

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 125

Ranbaxy Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 126

Strides Arcolab Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 127

Kite Pharma Raises USD409.7 Million in Public Offering of Shares 129

Galapagos Raises USD425 Million in Private Placement of Shares 131

Kite Pharma Announces Exercise of Over-Allotment Option for Public Offering of Shares for USD37.5 Million 132

Kite Pharma Raises USD28.2 Million Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 134

Kite Pharma Raises USD146.62 Million in IPO 136

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 138

Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 140

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 142

Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 144

Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 146

Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 148

Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 150

Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 152

Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 154

Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 156

Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 158

Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 160

Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 162

Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 164

Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 166

Gilead Sciences Raises USD500 Million in Public Offering of 2.35% Notes Due 2020 168

Gilead Sciences Raises USD1.8 Billion in Public Offering of 3.5% Notes Due 2025 170

Gilead Sciences Raises USD1.8 Billion in Public Offering of 4.5% Notes Due 2045 172

Gilead Sciences Completes Public Offering Of Notes Due 2019 For USD 500 Million 174

Gilead Sciences Completes Public Offering Of Notes Due 2044 For USD 1.75 Billion 176

Gilead Sciences Completes Public Offering Of Notes Due 2024 For USD 1.75 Billion 178

Sierra Oncology Acquires Momelotinib and Activin Receptor from Gilead Sciences 180

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences 182

Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 183

Gilead Sciences and Kite Pharma Acquire Cell Design Labs 185

Gilead Sciences Acquires Kite Pharma for USD11.9 Billion 187

Gilead Sciences May Acquire Incyte 189

Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 190

Gilead Sciences Acquires EpiTherapeutics for USD65 Million 191

Kite Pharma Acquires T-Cell Factory 192

Gilead Sciences Completes Acquisition Of YM BioSciences, Drug Development Company 193

Gilead Sciences Completes Acquisition Of Pharmasset For USD 11.2 Billion 195

Gilead Sciences Inc, Key Competitors 197

Gilead Sciences Inc, Key Employees 198

Gilead Sciences Inc, Other Locations 200

Gilead Sciences Inc, Subsidiaries 200

Gilead Sciences Inc, Joint Venture 204

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Gilead Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.